[1] |
Uitto J, Christiano AM. Molecular basis for the dystrophic forms of epidermolysis bullosa: mutations in the type VII collagen gene[J]. Arch Dermatol Res, 1994,287(1):16⁃22. doi: 10.1007/BF00 370713.
|
[2] |
Uitto J, Pulkkinen L, Christiano AM. Molecular basis of the dystrophic and junctional forms of epidermolysis bullosa: mutations in the type VII collagen and kalinin (laminin 5) genes[J]. J Invest Dermatol, 1994,103(5 Suppl):39S⁃46S. doi: 10. 1111/1523⁃1747.ep12398967.
|
[3] |
van den Akker PC, Jonkman MF, Rengaw T, et al. The international dystrophic epidermolysis bullosa patient registry: an online database of dystrophic epidermolysis bullosa patients and their COL7A1 mutations[J]. Hum Mutat, 2011,32(10):1100⁃1107. doi: 10.1002/humu.21551.
|
[4] |
Wertheim⁃Tysarowska K, Sobczyńska⁃Tomaszewska A, Kowalewski C, et al. The COL7A1 mutation database[J]. Hum Mutat, 2012,33(2):327⁃331. doi: 10.1002/humu.21651.
|
[5] |
Dourado Alcorte M, Sogayar MC, Demasi MA. Patent landscape of molecular and cellular targeted therapies for recessive dystrophic epidermolysis bullosa[J]. Expert Opin Ther Pat, 2019,29(5):327⁃337. doi: 10.1080/13543776.2019.1608181.
|
[6] |
徐哲, 林志淼. 两个隐性营养不良型大疱性表皮松解症家系COL7A1基因突变分析及产前诊断[J]. 中华皮肤科杂志, 2017,50(11):815⁃819. doi: 10.3760/cma.j.issn.0412⁃4030.2017. 11.009.
|
[7] |
Has C, Bauer JW, Bodemer C, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility[J]. Br J Dermatol, 2020,183(4):614⁃627. doi: 10.1111/bjd.18921.
|
[8] |
Järvikallio A, Pulkkinen L, Uitto J. Molecular basis of dystrophic epidermolysis bullosa: mutations in the type VII collagen gene (COL7A1)[J]. Hum Mutat, 1997,10(5):338⁃347. doi: 10.1002/(SICI)1098⁃1004(1997)10:5<338::AID⁃HUMU2>3.0.CO;2⁃B.
|
[9] |
陈劼, 吕军, 周迎春, 等. 遗传性大疱性表皮松解症367例问卷调查[J]. 中华皮肤科杂志, 2020,53(2):136⁃138. doi: 10. 35541/cjd.20190293.
|
[10] |
Bruckner⁃Tuderman L, Schnyder UW, Winterhalter KH, et al. Tissue form of type VII collagen from human skin and dermal fibroblasts in culture[J]. Eur J Biochem, 1987,165(3):607⁃611. doi: 10.1111/j.1432⁃1033.1987.tb11483.x.
|
[11] |
De Rosa L, Carulli S, Cocchiarella F, et al. Long⁃term stability and safety of transgenic cultured epidermal stem cells in gene therapy of junctional epidermolysis bullosa[J]. Stem Cell Reports, 2014,2(1):1⁃8. doi: 10.1016/j.stemcr.2013.11.001.
|
[12] |
Bauer JW, Koller J, Murauer EM, et al. Closure of a Large Chronic Wound through Transplantation of Gene⁃Corrected Epidermal Stem Cells[J]. J Invest Dermatol, 2017,137(3):778⁃781. doi: 10.1016/j.jid.2016.10.038.
|
[13] |
Hirsch T, Rothoeft T, Teig N, et al. Regeneration of the entire human epidermis using transgenic stem cells[J]. Nature, 2017,551(7680):327⁃332. doi: 10.1038/nature24487.
|
[14] |
Siprashvili Z, Nguyen NT, Gorell ES, et al. Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa[J]. JAMA, 2016,316(17):1808⁃1817. doi: 10.1001/jama.2016. 15588.
|
[15] |
Gaucher S, Lwin SM, Titeux M, et al. EBGene trial: patient preselection outcomes for the European GENEGRAFT ex vivo phase I/II gene therapy trial for recessive dystrophic epidermolysis bullosa[J]. Br J Dermatol, 2020,182(3):794⁃797. doi: 10.1111/bjd.18559.
|
[16] |
Wu X, Li Y, Crise B, et al. Transcription start regions in the human genome are favored targets for MLV integration[J]. Science, 2003,300(5626):1749⁃1751. doi: 10.1126/science.108 3413.
|
[17] |
Cattoglio C, Facchini G, Sartori D, et al. Hot spots of retroviral integration in human CD34+ hematopoietic cells[J]. Blood, 2007,110(6):1770⁃1778. doi: 10.1182/blood⁃2007⁃01⁃068759.
|
[18] |
Cattoglio C, Pellin D, Rizzi E, et al. High⁃definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors[J]. Blood, 2010,116(25):5507⁃5517. doi: 10.1182/blood⁃2010⁃05⁃283523.
|
[19] |
Fenjves ES, Yao SN, Kurachi K, et al. Loss of expression of a retrovirus⁃transduced gene in human keratinocytes[J]. J Invest Dermatol, 1996,106(3):576⁃578. doi: 10.1111/1523⁃1747.ep123 44976.
|
[20] |
Lwin SM, Syed F, Di WL, et al. Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa[J]. JCI Insight, 2019,4(11)doi: 10.1172/jci.insight.126243.
|
[21] |
Mellerio JE, Uitto J. Meeting Report: The First Global Congress on Epidermolysis Bullosa, EB2020 London: Toward Treatment and Cure[J]. J Invest Dermatol, 2020,140(9):1681⁃1687. doi: 10.1016/j.jid.2020.05.078.
|
[22] |
Karda R, Counsell JR, Karbowniczek K, et al. Production of lentiviral vectors using novel, enzymatically produced, linear DNA[J]. Gene Ther, 2019,26(3⁃4):86⁃92. doi: 10.1038/s41434⁃018⁃0056⁃1.
|